Cullgen
is a California-based biopharmaceutical company that researches and develops protein degraders and DAC therapies for diseases including cancer and inflammation... Read moreCullgen
is a California-based biopharmaceutical company that researches and develops protein degraders and DAC therapies for diseases including cancer and inflammation... Read more
News
May 04, 2026
Investing.com
Cullgen: Gyre Therapeutics completes $300 million acquisition of Cullgen
Mar 03, 2026
OINDPnews
Cullgen: Cullgen calls off merger with Pulmatrix
Jan 07, 2026
StreetInsider
Press Release: Cullgen : Cullgen Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Dec 12, 2025
StreetInsider
Press Release: Cullgen : Cullgen Reports Positive Results from Phase 1 Study of its Novel Non-Opioid Product Candidate CG001419 for Pain
Sep 18, 2025
GlobalNewswire
Press Release: Cullgen : Cullgen Completes Enrollment in Phase 1 Trial of its Novel Non-Opioid Pain Product Candidate CG001419
Jan 22, 2025
GlobalNewswire
Press Release: Cullgen : Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain
Nov 15, 2024
Medthority
Cullgen: Plumatrix to merge with Cullgen Inc.
Jan 16, 2024
Business Wire
Press Release: Cullgen : Cullgen Announces Additions to Board of Directors and Scientific Advisory Board
Jul 27, 2023
Business Wire
Press Release: Cullgen : Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients
Jun 19, 2023
Biospectrum Asia
Cullgen: US-based startup Cullgen inks billion-dollar deal with Japanese pharma firm Astellas, Read more
Cullgen Competitors
1
2
3
4
5
6
7
8
9
10